

Date: February 27, 2025

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block, Bandra-Kurla Complex,
Bandra (East), Mumbai 400 051.

SYMBOL: REMUS

Dear Sir/Madam,

Sub.: Outcome of Board Meeting

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company (the “**Board**”), in their meeting held today, i.e., February 27, 2025, has, *inter alia*, considered and approved the following:

- Voluntary adoption and implementation of Indian Accounting Standards (Ind AS):

To strengthen corporate governance and align accounting practices with international standards for greater transparency and comparability, the Board has approved the voluntary adoption and implementation of Indian Accounting Standards (Ind AS) with effect from April 1, 2024.

- Withdrawal of resolution for incorporation of a wholly owned subsidiary in the USA:

Since, the Company acquired Espee Global Holdings LLC on March 21, 2024, making it a subsidiary of the Company in the USA, the Board has decided to withdraw the earlier resolution passed for incorporating a wholly owned subsidiary in the USA, as previously intimated to the Exchange on August 04, 2023.

- Amendment to the “Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information”:

The Board has approved amendments to the Company’s Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information, made under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, to ensure compliance with applicable regulatory requirements.

Kindly note that the meeting of the Board of Directors of the Company commenced at **01:00 p.m. (IST)** and concluded at **03:00 p.m. (IST)**.

You are requested to take the above information on your record.

Thanking you.

Yours sincerely,
For, Remus Pharmaceuticals Limited

Deval Patel
Company Secretary and Compliance Officer
ICSI Membership No.: A60090

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536